BBA
Baker Bros. Advisors Portfolio holdings
AUM
$17.4B
1-Year Est. Return
131.5%
This Fund
S&P 500
1 Year Est. Return
+131.5%
AUM
$17.4B
AUM Growth
+$337M
(+2%)
Holding
93
Top Buys
| 1 | +$194M | |
| 2 | +$151M | |
| 3 | +$127M | |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$42M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$31.4M |
Top Sells
| 1 | +$63.8M | |
| 2 | +$51.4M | |
| 3 | +$38.4M | |
| 4 |
BioNTech
BNTX
|
+$25.6M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$22M |
Sector Composition
| 1 | Healthcare | 99.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LBRX
76
LB Pharmaceuticals
LBRX
$802M
| $4.93M | 0.03% |
200,000
|
|
||
77
Verastem
VSTM
$380M
| $3.1M | 0.02% |
+584,757
|
|
||
78
TScan Therapeutics
TCRX
$70.6M
| $2.81M | 0.02% |
2,784,792
|
|
||
79
Skye Bioscience
SKYE
$27.3M
| $968K | 0.01% |
1,575,243
+124,605
|
|
||
80
Sana Biotechnology
SANA
$918M
| $894K | 0.01% |
310,483
|
|
||
81
Aligos Therapeutics
ALGS
$35.3M
| $617K | ﹤0.01% |
83,055
|
|
||
82
Tyra Biosciences
TYRA
$1.99B
| $406K | ﹤0.01% |
10,607
|
|
||
83
Surrozen Inc Warrant
SRZNW
$51.4K
| $13.3K | ﹤0.01% |
833,333
|
|
||
84
Acrivon Therapeutics
ACRV
$68.5M
| – | – |
-22,809
|
|
||
|
85
BioCryst Pharmaceuticals
BCRX
$2.26B
| – | – |
-2,822,727
|
|
||
86
4D Molecular Therapeutics
FDMT
$518M
| – | – |
-475,737
|
|
||
87
KALA BIO
KALA
$41.5M
| – | – |
-36,081
|
|
||
88
Nuvalent
NUVL
$8.72B
| – | – |
-143,937
|
|
||
89
Ultragenyx Pharmaceutical
RARE
$2.36B
| – | – |
-2,772,692
|
|
||
|
TERN
90
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-950,000
|
|
||
91
Vir Biotechnology
VIR
$1.61B
| – | – |
-542,539
|
|
||
|
VTYX
92
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-2,349,280
|
|